Sponsor

Eidos Therapeutics, a BridgeBio company

Clinical research sponsor

Published trials7
Recruiting shown3
Roles2
SourceClinicalTrials.gov

Clinical trials

7 shown
Cardiac Magnetic Resonance and Echocardiography Study With AcoramidisNCT07695701 · lead sponsor · 2026-07-01
RECRUITING
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantNCT06563895 · lead sponsor · 2025-05-12
RECRUITING
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)NCT07116473 · lead sponsor · 2026-11-01
NOT_YET_RECRUITING
Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)NCT04882735 · lead sponsor · 2021-09-08
WITHDRAWN
Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid PolyneurophathyNCT04418024 · lead sponsor · 2020-10-21
WITHDRAWN
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid CardiomyopathyNCT03860935 · lead sponsor · 2019-03-19
COMPLETED
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEFNCT05577819 · collaborator · 2020-10-02
RECRUITING

Sponsor roles

lead sponsor6
collaborator1

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.